Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1998-8-4
|
pubmed:abstractText |
1. It has been hypothesized that 5-HT1A autoreceptor antagonists may enhance the therapeutic efficacy of SSRIs and other antidepressants. Although early clinical trials with the beta-adrenoceptor/5-HT1 ligand, pindolol, were promising, the results of recent more extensive trials have been contradictory. Here we investigated the actions of pindolol at the 5-HT1A autoreceptor by measuring its effect on 5-HT neuronal activity and release in the anaesthetized rat. 2. Pindolol inhibited the electrical activity of 5-HT neurones in the dorsal raphe nucleus (DRN). This effect was observed in the majority of neurones tested (10/16), was dose-related (0.2-1.0 mg kg(-1), i.v.), and was reversed by the 5-HT1A receptor antagonist, WAY 100635 (0.1 mg kg(-1), i.v.), in 6/7 cases tested. 3. Pindolol also inhibited 5-HT neuronal activity when applied microiontophoretically into the DRN in 9/10 neurones tested. This effect of pindolol was current-dependent and blocked by co-application of WAY 100635 (3/3 neurones tested). 4. In microdialysis experiments. pindolol caused a dose-related (0.8 and 4 mg kg(-1), i.v.) fall in 5-HT levels in dialysates from the frontal cortex (under conditions where the perfusion medium contained 1 microM citalopram). In rats pretreated with WAY 100635 (0.1 mg kg(-1), i.v.), pindolol (4 mg kg(-1), i.v.) did not decrease, but rather increased 5-HT levels. 5. We conclude that, under the experimental conditions used in this study, pindolol displays agonist effects at the 5-HT1A autoreceptor. These data are relevant to previous and ongoing clinical trials of pindolol in depression which are based on the rationale that the drug is an effective 5-HT1A autoreceptor antagonist.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0007-1188
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
124
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
206-12
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:9630361-Action Potentials,
pubmed-meshheading:9630361-Animals,
pubmed-meshheading:9630361-Iontophoresis,
pubmed-meshheading:9630361-Male,
pubmed-meshheading:9630361-Neurons,
pubmed-meshheading:9630361-Pindolol,
pubmed-meshheading:9630361-Raphe Nuclei,
pubmed-meshheading:9630361-Rats,
pubmed-meshheading:9630361-Rats, Sprague-Dawley,
pubmed-meshheading:9630361-Receptors, Serotonin,
pubmed-meshheading:9630361-Receptors, Serotonin, 5-HT1,
pubmed-meshheading:9630361-Serotonin Receptor Agonists
|
pubmed:year |
1998
|
pubmed:articleTitle |
Electrophysiological and neurochemical evidence that pindolol has agonist properties at the 5-HT1A autoreceptor in vivo.
|
pubmed:affiliation |
University Department of Clinical Pharmacology, Radcliffe Infirmary, Oxford.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|